Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × ribociclib × Clear all

Phase

Phase 1 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 22 Neoplasms by Site 2 Neoplasms 2 Neoplasm Metastasis 2 Multiple Endocrine Neoplasia Type 1 2 Breast Diseases 2 Unilateral Breast Neoplasms 1 Recurrence 1 Osteitis Deformans 1 Hereditary Sensory and Autonomic Neuropathies 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Breast Neoplasms, Male 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 23 Rituximab 15 Gemcitabine 11 Cisplatin 11 pomalidomide 10 Paclitaxel 10 Lenalidomide 9 Bortezomib 9 Carboplatin 8 Cyclophosphamide 7 carfilzomib 6 Drug Therapy 5 Cytarabine 5 selinexor 4 ibrutinib 4 daratumumab 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 ofatumumab 2 galiximab 2 eculizumab 2 durvalumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06760637 2026-03-02

FourLight-3

Pfizer

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡